Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis
Launched by FONDAZIONE ITALIANA LINFOMI - ETS · May 29, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying elderly patients who are 65 years and older and have been newly diagnosed with classical Hodgkin lymphoma, a type of cancer that affects the lymphatic system. The goal of the study is to create a tool that can help predict how well these patients might do with treatment. To do this, researchers will assess patients' overall health through a Comprehensive Geriatric Assessment (CGA) and track their progress over time.
To participate in this study, patients must be at least 65 years old, have a confirmed diagnosis of classical Hodgkin lymphoma, and have not received any treatment for their cancer before. Participants will undergo an initial health evaluation and provide consent to join the study. Throughout the trial, researchers will gather information to better understand how to support elderly patients facing this diagnosis. This is an important step in improving care for older adults with cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Diagnosis of classical Hodgkin Lymphoma
- • 2. Age ≥ 65 year
- • 3. Evaluation of Comprehensive Geriatric Assessment at baseline
- • 4. Signed informed consent
- • 5. Previously untreated patients
- Exclusion Criteria:
- • None
About Fondazione Italiana Linfomi Ets
Fondazione Italiana Linfomi - ETS is a leading research organization dedicated to advancing the understanding and treatment of lymphoid malignancies. With a focus on promoting clinical trials and innovative therapeutic approaches, the foundation collaborates with healthcare professionals, academic institutions, and pharmaceutical companies to enhance patient care and outcomes. Its mission encompasses fostering research initiatives, facilitating education, and supporting the development of new strategies to combat lymphomas, ultimately aiming to improve the quality of life for patients affected by these diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sassuolo, , Italy
Torino, , Italy
Padova, , Italy
Ravenna, , Italy
Rimini, , Italy
Aviano, , Italy
Bari, , Italy
Barletta, , Italy
Castelfranco Veneto, , Italy
Matera, , Italy
Meldola, , Italy
Milano, , Italy
Parma, , Italy
Pavia, , Italy
Roma, , Italy
Tricase, , Italy
Roma, , Italy
Siena, , Italy
Novara, , Italy
Alessandria, , Italy
Ancona, , Italy
Avellino, , Italy
Brescia, , Italy
Cagliari, , Italy
Campobasso, , Italy
Cosenza, , Italy
Firenze, , Italy
Frosinone, , Italy
Ivrea, , Italy
Milano, , Italy
Milano, , Italy
Napoli, , Italy
Padova, , Italy
Palermo, , Italy
Perugia, , Italy
Piacenza, , Italy
Reggio Emilia, , Italy
Rozzano, , Italy
Sondrio, , Italy
Terni, , Italy
Torino, , Italy
Milano, , Italy
Roma, , Italy
Treviso, , Italy
Patients applied
Trial Officials
Vittorio Ruggero Zilioli, MD
Principal Investigator
SC Ematologia, ASST Grande Ospedale Metropolitano Niguarda, Milano - Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials